5-benzyloxy-2-(2-chloro-4-nitrophenyl)benzothiazole | 162374-68-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 5-benzyloxy-2-(2-chloro-4-nitrophenyl)benzothiazole
• 英文别名: 2-(2-Chloro-4-nitrophenyl)-5-phenylmethoxy-1,3-benzothiazole
• CAS: 162374-68-7
• 化学式: C₂₀H₁₃ClN₂O₃S
• 分子量: 396.854
• InChiKey: KYJIXBFRHDYWKG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  96.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-benzyloxy-2-(2-chloro-4-nitrophenyl)benzothiazole 在 tin(ll) chloride 作用下， 以 乙醇 为溶剂， 反应 4.0h， 以90%的产率得到2-(4-Amino-2-chlorophenyl)-5-benzyloxybenzothiazole
  参考文献：
  名称：

  Antitumor Benzothiazoles. 3. Synthesis of 2-(4-Aminophenyl)benzothiazoles and Evaluation of Their Activities against Breast Cancer Cell Lines in Vitro and in Vivo

  摘要：

  A new series of 2-(4-aminophenyl)benzothiazoles substituted in the phenyl ring and benzothiazole moiety has been synthesized by simple, high-yielding routes. The parent molecule 5a shows potent inhibitory activity in vitro in the nanomolar range against a panel of human breast cancer cell lines, but is inactive (IC50 > 30 mu M) against other cell types: activity against the sensitive breast lines MCF-7 and MDA 468 is characterized by a biphasic dose-response relationship. Structure-activity relationships derived using these cell types has revealed that activity follows the heterocyclic sequence benzothiazole > benzoxazole much greater than benzimidazole and that 2-(4-aminophenyl)benzothiazoles bearing a 3'-methyl- 9a, 3'-bromo- 9c, 3'- iodo- 9f, and 3'-chloro-substituent 9i are especially potent and their activity extends to ovarian, lung, and renal cell lines. Four compounds have been evaluated in vivo against human mammary carcinoma models in nude mice. Compound 9a showed the most potent growth inhibition against the ER(+) (MCF-7 and BO) and ER(-) (MT-1 and MT-3) tumors. Our efforts to identify a pharmacological mechanism of action for these intriguing compounds have not, as yet, been successful.

  DOI：

  10.1021/jm9600959
• 作为产物：
  描述：

  3-苄氧基苯胺 在 劳森试剂 、 吡啶 、 sodium hydroxide 、 potassium hexacyanoferrate(III) 作用下， 以 乙醇 、 氯苯 为溶剂， 反应 5.5h， 生成 5-benzyloxy-2-(2-chloro-4-nitrophenyl)benzothiazole
  参考文献：
  名称：

  Antitumor Benzothiazoles. 3. Synthesis of 2-(4-Aminophenyl)benzothiazoles and Evaluation of Their Activities against Breast Cancer Cell Lines in Vitro and in Vivo

  摘要：

  A new series of 2-(4-aminophenyl)benzothiazoles substituted in the phenyl ring and benzothiazole moiety has been synthesized by simple, high-yielding routes. The parent molecule 5a shows potent inhibitory activity in vitro in the nanomolar range against a panel of human breast cancer cell lines, but is inactive (IC50 > 30 mu M) against other cell types: activity against the sensitive breast lines MCF-7 and MDA 468 is characterized by a biphasic dose-response relationship. Structure-activity relationships derived using these cell types has revealed that activity follows the heterocyclic sequence benzothiazole > benzoxazole much greater than benzimidazole and that 2-(4-aminophenyl)benzothiazoles bearing a 3'-methyl- 9a, 3'-bromo- 9c, 3'- iodo- 9f, and 3'-chloro-substituent 9i are especially potent and their activity extends to ovarian, lung, and renal cell lines. Four compounds have been evaluated in vivo against human mammary carcinoma models in nude mice. Compound 9a showed the most potent growth inhibition against the ER(+) (MCF-7 and BO) and ER(-) (MT-1 and MT-3) tumors. Our efforts to identify a pharmacological mechanism of action for these intriguing compounds have not, as yet, been successful.

  DOI：

  10.1021/jm9600959

文献信息

• BENZAZOLE COMPOUNDS FOR USE IN THERAPY
  申请人：CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED

  公开号：EP0721336A1

  公开（公告）日：1996-07-17
• US5874431A
  申请人：——

  公开号：US5874431A

  公开（公告）日：1999-02-23
• [EN] BENZAZOLE COMPOUNDS FOR USE IN THERAPY<br/>[FR] COMPOSES DE BENZAZOLE A USAGE THERAPEUTIQUE
  申请人：——

  公开号：WO1995006469A1

  公开（公告）日：1995-03-09

  [EN] There are disclosed herein benzazole compounds, exemplified by 2-(4-aminophenyl)benzothiazole and analogues or salts thereof, which exhibit very significant selective cytotoxic activity in respect of tumour cells, especially breast cancer cells, and which provide potentially useful chemotherapeutic agents for treatment of breast cancer.
  [FR] L'invention concerne des composés de benzazole, à l'exemple du 2-(4-aminophényle)benzothiazole et de ses analogues ou sels, démontrant une activité cytotoxique sélective très remarquable à l'égard des cellules tumorales, notamment des cellules du cancer du poumon; ces composés constituent des agents chimiothérapeutiques potentiellement utiles pour le traitement du cancer du poumon.
• Antitumor Benzothiazoles. 3. Synthesis of 2-(4-Aminophenyl)benzothiazoles and Evaluation of Their Activities against Breast Cancer Cell Lines <i>in </i><i>Vitro </i>and <i>in Vivo</i>
  作者：Dong-Fang Shi、Tracey D. Bradshaw、Samantha Wrigley、Carol J. McCall、Peter Lelieveld、Iduna Fichtner、Malcolm F. G. Stevens

  DOI：10.1021/jm9600959

  日期：1996.1.1

  A new series of 2-(4-aminophenyl)benzothiazoles substituted in the phenyl ring and benzothiazole moiety has been synthesized by simple, high-yielding routes. The parent molecule 5a shows potent inhibitory activity in vitro in the nanomolar range against a panel of human breast cancer cell lines, but is inactive (IC50 > 30 mu M) against other cell types: activity against the sensitive breast lines MCF-7 and MDA 468 is characterized by a biphasic dose-response relationship. Structure-activity relationships derived using these cell types has revealed that activity follows the heterocyclic sequence benzothiazole > benzoxazole much greater than benzimidazole and that 2-(4-aminophenyl)benzothiazoles bearing a 3'-methyl- 9a, 3'-bromo- 9c, 3'- iodo- 9f, and 3'-chloro-substituent 9i are especially potent and their activity extends to ovarian, lung, and renal cell lines. Four compounds have been evaluated in vivo against human mammary carcinoma models in nude mice. Compound 9a showed the most potent growth inhibition against the ER(+) (MCF-7 and BO) and ER(-) (MT-1 and MT-3) tumors. Our efforts to identify a pharmacological mechanism of action for these intriguing compounds have not, as yet, been successful.